Your session is about to expire
← Back to Search
Vaccines for Blood Cancer
Study Summary
This trial is testing how well vaccines work in people with certain types of blood cancers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have CLL.I am currently being treated with a BTK inhibitor and not receiving the HEPLISAV-B vaccine.I've been on BTK inhibitor treatment for 6+ months and can pause it for vaccinations, without prior treatment issues.I have a type of non-Hodgkin lymphoma.I am 18 years old or older.I am not currently undergoing any cancer treatment.You are currently receiving treatment with a BCL-2 inhibitor or you have previously received treatment.I have not had chemotherapy within the last 2 weeks.I have received IVIG treatment within the last 2 months.I have been on a BTK inhibitor for over 6 months and can pause it for up to 7 weeks for vaccination.I have proof of a negative response to the Hepatitis-B vaccine.I have been diagnosed with a type of non-Hodgkin lymphoma.I have a genetic condition that weakens my immune system.I have had a stem cell transplant from a donor.I have had cancer treatment before but am not on any treatment now.I have not received any treatment for my cancer.I have received anti-CD20 or anti-CD19 therapy within the last 6 months.I have been diagnosed with a type of non-Hodgkin lymphoma.I am currently pregnant.You have had a serious allergic reaction to vaccines in the past.I have not received any treatment for my cancer.I have had cancer treatment before but am not on any treatment now.I am currently being treated with a BCL-2 inhibitor.I have not had cellular therapy like CAR-T in the last 12 months.I am currently on targeted cancer therapy.This criterion does not provide enough information for a summary.I understand this is a research study and I can give my consent.I am currently being treated with a BTK inhibitor and not receiving the HEPLISAV-B vaccine.
- Group 1: Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia
- Group 2: Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia - Treatment with Targeted Therapies
- Group 3: Chronic Lymphocytic Leukemia Not Receiving Active Treatment
- Group 4: Chronic Lymphocytic Leukemia Treatment Break for BTKi
- Group 5: Chronic Lymphocytic Leukemia Treatment Naive
- Group 6: Chronic Lymphocytic Leukemia Treatment with BTKi
- Group 7: Follicular Lymphoma
- Group 8: Follicular Lymphoma Treatment Naive
- Group 9: Participants diagnosed with Chronic Lymphocytic Leukemia (CLL)
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current enrollment size of this clinical trial?
"Affirmative. Clinicaltrials.gov verifies that this medical trial was initially posted on September 14th 2022 and is continuing to seek new participants at present time. 500 individuals are needed for the study which will take place in one facility."
Have any prior investigations investigated the efficacy of Heplisav -B?
"Currently, Heplisav -B is the subject of 76 live clinical trials; 20 of them are in Phase 3. In Nantwich, Cheshire, Surrey alone there are several studies looking into this drug and a total of 1054 sites across the world conducting research on it."
Is there currently an opportunity for enrollment in this medical experiment?
"Affirmative, the details available on clinicaltrials.gov demonstrate that this research project is actively seeking participants. It was first published September 14th 2022 and has been recently updated November 23rd of the same year. In total, 500 individuals are desired for a single location trial."
To what extent is Heplisav-B a potential hazard for patients?
"Heplisav-B is approved at a safety rating of 3, as the medication has completed Phase 4 trials and thus been deemed suitable for use."
What illnesses does Heplisav-B provide remedial action for?
"Heplisav-B is commonly administered to treat hepatitis A, and has also proven successful in managing streptococcus pneumoniae infection, traumatic injuries, and viral hepatitis b."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- National Institutes of Health Clinical Center: < 48 hours
Share this study with friends
Copy Link
Messenger